References

Citations

1. Zhang X, et al. (2005). Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Archives of Internal Medicine, 165(16): 1890–1895.

2. Speroff L, Fritz MA (2005). Menopause and the perimenopausal transition. In Clinical Gynecologic Endocrinology and Infertility, 7th ed., pp. 621–688. Philadelphia: Lippincott Williams and Wilkins.

3. Joffe H, et al (2003). Assessment and treatment of hot flushes and menopausal mood disturbance. Psychiatric Clinics of North America, 26(3): 563–580.

4. Taguchi A, et al. (2004). Effect of estrogen use on tooth retention, oral bone height, and oral bone porosity in Japanese postmenopausal women. Menopause, 11(5): 556–562.

5. Rossouw JE, et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3): 321–333.

6. Million Women Study Collaborators (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 362(9382): 419–427.

7. Shumaker SA, et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative memory study: A randomized controlled trial. JAMA, 289(20): 2651–2662.

8. Rossouw JE, et al. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297(13): 1465–1477.

9. North American Menopause Society (2004). Treatment of menopause-associated vasomotor symptoms: Position statement of the North American Menopause Society. Menopause, 11(1): 11–33.

10. Stearns V, et al. (2003). Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial. JAMA, 289(21): 2827–2834.

11. Pandya KJ, et al. (2000). Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. Annals of Internal Medicine, 132(10): 788–793.

12. Watt PJ, et al. (2003). A holistic programmatic approach to natural hormone replacement. Family and Community Health, 26(1): 53–63.

13. North American Menopause Society (2005). The role of testosterone therapy in postmenopausal women: Position statement of the North American Menopause Society. Menopause, 12(5): 497–511.

14. American College of Obstetricians and Gynecologists (2003). Statement of the American College of Obstetricians and Gynecologists on hormone therapy for the prevention and treatment of postmenopausal osteoporosis. ACOG News Release. Available online: http://www.acog.com/from_home/publications/press_releases/nr10-07-03.cfm.

15. Women's Health Initiative Steering Committee (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA, 291(14): 1701–1712.

16. North American Menopause Society (2007). Position statement: Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause, 14(2): 168–182.

17. Espeland MA, et al. (2004). Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA, 291(24): 2959–2968.

18. Beral V, et al. (2007). Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet, 369(9574): 1703–1710.

19. American College of Obstetricians and Gynecologists Women's Health Care Physicians (2004). Breast cancer. Obstetrics and Gynecology, 104(4, Suppl): 11S–16S.

20. American College of Obstetricians and Gynecologists Women's Health Care Physicians (2004). Stroke. Obstetrics and Gynecology, 104(4, Suppl): 97S–105S.

21. Speroff L, Fritz MA (2005). Postmenopausal hormone therapy. In Clinical Gynecologic Endocrinology and Infertility, 7th ed., pp. 689–777. Philadelphia: Lippincott Williams and Wilkins.

22. Grady D, et al. (2003). Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstetrics and Gynecology, 102(6): 1233–1239.

23. Guttuso T Jr, et al. (2003). Gabapentin's effects on hot flashes in postmenopausal women: A randomized controlled trial. Obstetrics and Gynecology, 101(2): 337–345.

24. American College of Obstetricians and Gynecologists (2001, reaffirmed 2006). Use of botanicals for management of menopausal symptoms. ACOG Practice Bulletin No. 28. Obstetrics and Gynecology, 97(6, Suppl): 1–11.

25. Cooper A, et al. (1998). Systemic absorption of progesterone from Progest cream in post-menopausal women. Lancet, 351(9111): 1255–1256.

26. Hermann AC, et al. (2005). Over-the-counter progesterone cream produces significant drug exposure compared to a Food and Drug Administration-approved oral progesterone product. Journal of Clinical Pharmacology, 45(6): 614–619.

27. Prestwood KM, et al. (2003). Ultralow-dose micronized 17 B-estradiol and bone density and bone metabolism in older women. JAMA, 290(8): 1042–1048.

28. Newton KM, et al. (2006). Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo. Annals of Internal Medicine, 145(12): 869–879.

29. Grady D (2006). Management of menopausal symptoms. New England Journal of Medicine, 355(22): 2338–2347.

Other Works Consulted

• American Association of Clinical Endocrinologists Menopause Guidelines Revision Task Force (2006). American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocrine Practice, 12(3): 315–337.

• Grady D, Barrett-Connor E (2008). Menopause. In L Goldman, D Ausiello, eds., Cecil Medicine, 23rd ed., pp. 1857–1868. Philadelphia: Saunders Elsevier.

• Shifren JL, Schiff I (2007). Menopause. In JS Berek, ed., Berek and Novak's Gynecology, 14th ed., pp. 1323–1340. Philadelphia: Lippincott Williams and Wilkins.

• U.S. Preventive Services Task Force (2005). Hormone therapy for the prevention of chronic conditions in postmenopausal women: Recommendations from the U.S. Preventive Services Task Force. Annals of Internal Medicine, 142(10): 855–860.